Elizabeth Jocelyn Mascull – Trademark Portfolio
Entity Type: 01
Elizabeth Jocelyn Mascull holds 21 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 16 filings in this category. The portfolio also extends into Class 12 (Vehicles) across 5 Nice Classification classes. Currently, 8 trademarks are registered and 5 are pending. Notable registered marks include SPEX, ZYGO, STYLO, ADAPTA, and XLELLA.
c/- Medifab,
32 Detroit Drive, Izone Business Hub Rol
Showing of trademarks Trademarks
Trademark Classifications
Elizabeth Jocelyn Mascull's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does Elizabeth Jocelyn Mascull have?
Elizabeth Jocelyn Mascull has 21 U.S. trademarks filed with the USPTO. Of these, 8 registered, 5 pending.
What trademark classes does Elizabeth Jocelyn Mascull file in?
Elizabeth Jocelyn Mascull files trademarks across 5 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 12 (Vehicles), Class 20 (Furniture), Class 42 (Computer & Scientific), Class 9 (Computers & Electronics). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are Elizabeth Jocelyn Mascull's most well-known trademarks?
Elizabeth Jocelyn Mascull's registered trademark portfolio includes well-known marks such as SPEX, ZYGO, STYLO, ADAPTA, and XLELLA. These are among 8 currently registered trademarks in the portfolio.
What is Elizabeth Jocelyn Mascull's trademark registration success rate?
Elizabeth Jocelyn Mascull has a 100% trademark registration rate, with 8 out of 8 resolved applications resulting in successful registration. Currently, 5 applications are pending review.